Innovation Pharmaceuticals Inc (IPIX)

[kfcyahoo]

Makes sense, the mild to moderate study enrolled 115 patients at 9 sites in 8 to 9 months.

115pts/9months/9 sites)= 1.42 pts/month per site. What should be mentioned is that 80% of cases are mild to moderate, while 20% fall into the moderate to severe.

CTIX has designed the study such that of 189 patients, 81 pts(42.9%) will receive placebo, 81 pts(42.9%) will receive the 300 mg daily dose(150 mg twice/day), and 27 pts(14.2%) will receive 400mg daily(200mg twice/day).

If the severe cases get the higher dosage of 400mg daily, then an enrollment rate of approximately 1.5 pts/month per location is feasible.

https://www.aad.org/media/stats/conditions/psoriasis